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ABSTRACT
Objective: To examine the effect of the first
introduction of measles vaccine (MV) in Guinea-Bissau
in 1979.
Setting: Urban community study of the anthropometric
status of all children under 6 years of age.
Participants: The study cohort included 1451 children
in December 1978; 82% took part in the anthropometric
survey. The cohort was followed for 2 years.
Intervention: In December 1979, the children were re-
examined anthropometrically. The participating children,
aged 6 months to 6 years, were offered MV if they did
not have a history of measles infection. There were no
routine vaccinations in 1979–1980.
Primary and secondary outcome measures: Age-
adjusted mortality rate ratios (MRRs) for measles
vaccinated and not vaccinated children; changes in
nutritional status.
Results: The nutritional status deteriorated significantly
from 1978 to 1979. Nonetheless, children who received
MV at the December 1979 examination had significantly
lower mortality in the following year (1980) compared
with the children who had been present in the
December 1978 examination but were not measles
vaccinated. Among children still living in the community
in December 1979, measles-vaccinated children aged 6–
71 months had a mortality rate of
18/1000 person-years during the following year
compared with 51/1000 person-years for absent
children who were not measles vaccinated (MRR=0.30
(0.12–0.73)). The effect of MV was not explained by
prevention of measles infection as the unvaccinated
children did not die of measles infection.
Conclusions: MV may have beneficial non-specific
effects on child survival not related to the prevention of
measles infection.
INTRODUCTION
The general childhood immunisation pro-
gramme became widespread in Africa only
after UNICEF’s Universal Childhood
Immunization programme in the mid-1980s.
At the time the recommended schedule was
BCG and oral polio vaccine (OPV) at birth,
diphtheria–tetanus–pertussis (DTP) and OPV
in three doses with an interval of 4 weeks,
starting at 2 or 3 months of age, plus measles
vaccine (MV) at 9 months and booster doses
of DTP and OPV in the second year of life.
There are surprisingly few studies of what the
introduction of different vaccines meant for
overall child survival.1
At the Bandim Health Project (BHP), we
have followed a small urban community,
Bandim, in the capital of Guinea-Bissau since
1978 and we took part in the sequential
introduction of the different vaccines before
a full-ﬂedged national programme was imple-
mented in 1986 with UNICEF support. We
followed the community with a demographic
surveillance system from December 1978.
Strengths and limitations of this study
▪ There are few studies of what happened when
the measles vaccine was introduced in low
income countries. Since 1978, we have followed
an urban community in Bissau, the capital of
Guinea-Bissau, with anthropometric surveys.
▪ More than 80% of children <6 years of age parti-
cipated in the nutritional surveys and the
measles vaccination campaign.
▪ When the measles vaccine was introduced in
1979, mortality declined threefold from 1 year to
the next. The difference was not explained by
changes in nutritional status.
▪ Although this is not a randomised study, it sug-
gests strong beneficial non-specific effects of
measles vaccine. Since measles is soon to be
eradicated, it is well to remember that MV has
beneficial non-specific effects on child survival.
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MV was offered to all children aged 6 months to
6 years of age at the ﬁrst general vaccination campaign
in December 1979.2 We therefore compared mortality in
the prevaccination year with the year following the intro-
duction of MV. There were no computers in Bissau at
the time and we have previously only been able to
provide an assessment of MV for children aged
6–36 months based on tallying the number of children
under observations, the number of vaccinations and the
number of deaths. The tallying methods provided
limited possibilities for examining and controlling for
the impact of age, nutritional status and other factors.2
Hence, to better assess the effect of MV, we have now
digitalised the original data and reanalysed the data
using more advanced statistical methods. Whereas the
data previously have mainly been described in terms of
the change in mortality rates in the community before
and after the introduction of MV, we have now also com-
pared the mortality of children who were eligible for MV
and did or did not receive MV.
METHODS
Background
In the fall of 1978, a ‘de jure’ census was completed in
the study area Bandim. After numbering the houses on
a map, each household was visited and all the indivi-
duals living there were recorded with name, age and
relation to the household head. An ongoing registration
of births and deaths was set up employing local commu-
nity activists who were trained and supervised by us. In
December 1978, we conducted an anthropometric
examination of all children <6 years of age to be able to
assess malnutrition in this community3 (ﬁgure 1).
Bandim had eight subdistricts and the inline examina-
tions were conducted over 1–2 days in each of these sub-
districts. Children absent on these days—usually because
they were travelling—were not examined.
In early 1979, the area experienced a severe measles
epidemic.3 4 At the re-examination in December 1979,
the children who were present and older than 6 months
were offered MV (Attenuvax, Merck-Sharp & Dome).
However, two groups were not offered MV: ﬁrst, children
whose mother or guardian declared that the child had
had measles in the 1979 epidemic or earlier; and
second, children whose mother or guardian declared
that the child had been vaccinated at the time of the
epidemic. This latter group is called ‘suspected MV’ in
the present analysis. When we conducted the
re-examination, we believed that the children had
received MV at the child clinic in town.
The measles vaccinations we administered were
recorded on the child’s growth card. Our team did not
register who received MV, but we know from later
inspection of these cards that children who were
present, had not had measles infection, had not had
‘suspected MV’ and were at least 6 months old did
receive MV.2
There was no community vaccination programme at
the time in Guinea-Bissau. As shown below, the chil-
dren who had ‘suspected MV’ had either received no
MV or an MV which was no longer effective. Hence,
the children not attending the examination in
December 1979 had not received an effective vaccine
and we considered these children MV unvaccinated in
the present analyses. The children not attending the
1979 examination could be different from the ones
who were attending. We have therefore used data from
the 1978 examination to test whether mortality was
likely to differ for children attending and not attending
the examinations.
Follow-up
The sequence of events has been depicted in ﬁgure 1. A
new census was conducted in the area in December
1981 to January 1982. Hence, through the demographic
surveillance system, survival information was available for
all children registered in the fall of 1978 and in
December 1979. We followed the ﬁrst cohort from the
date of the scheduled 1978 examination until the date
of the scheduled 1979 examination or until death or
until the date of moving away from the study area,
whichever came ﬁrst. For the second period, follow-up
started at the scheduled 1979 examination and ended
on 1 December 1980, or at death or on the date of
moving away (ﬁgure 1). A new round of measles vaccina-
tions started in December 1980, and we therefore
decided to end follow-up before the unvaccinated chil-
dren were likely to receive vaccination.
Figure 1 The duration of
phases (first examination, second
examination and follow-up
periods) is shown with thick lines.
Four examples of follow-up
periods are shown with thin lines.
Follow-up starts on a scheduled
examination date; the first and the
second follow-up periods do not
overlap for a specific individual.
MV, measles vaccine.
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Data control
The data from the two examinations in December 1978
and December 1979 were linked to the population
register to facilitate long-term follow-up. Using the ori-
ginal examination forms, key variables for the survival
analysis including date of birth, sex and examination
dates were checked for consistency. The consistency
and inconsistencies in relation to the previous analysis2
have been described in the online supplementary
material.
Analysis and statistical method
The children with a weight or length recorded in the
1978 examination or the 1979 examination, respectively,
have been considered ‘examined’ in the respective year
and the other children registered but without a weight
or height measured have been considered ‘absent’.
Furthermore, the children examined in the 1979
examination were classiﬁed as ‘measles vaccinated′’, ‘sus-
pected MV’ and ‘previous measles infection’ according
to the information provided during the examination.
The mortality of different groups has been compared
using age-speciﬁc mortality rate ratios (MRRs) with age
being age at start of a follow-up period. The reported
CIs are exact. In this way, we have estimated age-speciﬁc
and age-adjusted MRRs for several factors, including sex,
examination status and vaccination status. To examine
whether there were major differences between children
being present and absent from the examination in
December 1979, we used the anthropometric informa-
tion from children who had taken part in the 1978
examination. The WHO z-scores for child growth were
used to compare weight and height of children who par-
ticipated or who were absent in the 1979 examination.5
We also compared the nutritional status of the 1978 and
the 1979 cohorts.
Background factors such as household type (polyg-
amy/monogamy; sex of household head), number of
generations in the household and ethnicity were
available in the data and could be used for example, in
a Poisson regression. However, owing to the limited
number of events, we have not adjusted for these vari-
ables in our survival analyses as such adjustment would
entail a substantial risk of overﬁtting the model.
Ethics
The study of nutritional status was planned between the
SAREC (Swedish Agency for Research Collaboration
with Developing Countries) and the Ministry of Health
(MOH) in Guinea-Bissau. At the time, there was no
national committee for research ethics. Interviews and
anthropometric examinations were explained to the
parents in terms of the MOH needing to know why mor-
tality was so high. Participation was assumed to reﬂect
parental consent.
RESULTS
In December 1978, 6217 individuals were registered in
the census in Bandim; 1451 were <6 years of age and
were invited to take part in the 1978 examination and
82% (1187/1451) participated (ﬁgure 2). In December
1979, 86% of children <6 years of age (1168/1355) took
part in the 1979 examination (ﬁgure 2).
As seen in table 1, mortality rates were very high
during the ﬁrst year of the study (table 1A). Mortality
declined markedly in the second year of the study
(table 1B). The age-adjusted MRR for the second year
compared with the ﬁrst year was 0.30 (0.21 to 0.45).
Clinical examination and simple treatment was offered
in connection with the anthropometric examinations in
December 1978, but mortality during the subsequent
year was not lower for the children who attended than
for those who were absent, the MRR being 1.35 (0.80 to
2.28) (table 2). In stark contrast, in the second year, the
MRR was 0.49 (0.22 to 1.09) for those who were clinic-
ally examined compared with those who were absent in
December 1979 (table 2).
The following analysis is restricted to the age group
6–71 months because these children were eligible to
receive MV. The mortality rate of ‘absent’ children was
similar in the ﬁrst and the second years of the study, the
MRR being 0.89 (0.36 to 2.22) (table 2). Hence, the
decline in mortality between 1979 and 1980 occurred
among children who were present at the nutritional
examinations. We compared the nutritional status in
December 1978 and in December 1979 by calculating
the age-speciﬁc z-score means and furthermore using a
mixed effects models with a random intercept on child
to estimate z-score differences between years (table 3).
Age and year were included in the mixed effects model
as predictors. All three z-scores were signiﬁcantly lower
in 1979 than in 1978 (p<0.001). Hence, the better sur-
vival during the second year (1980) was not explained
by improved nutritional status. Using a linear normal
model, there was no signiﬁcant difference in 1978
between those who were examined and those who were
absent in December 1979, the mean differences in
z-scores for weight-for-age, height-for-age and
weight-for-height being 0.07, 0.09 and 0.06, respectively,
and the p values being 0.51, 0.50 and 0.61.
Apart from a clinical examination by a paediatrician
which took place at both examinations, measles vaccin-
ation was the only intervention offered to children in
the 1979 examination. Compared with the children who
were present in December 1978 (did not receive MV),
the MRR for children aged 6–71 months who received
MV in December 1979 was 0.19 (0.10–0.36).
There was also a marked difference in mortality for
children who received MV compared with absent chil-
dren who did not receive MV in December 1979
(MRR=0.30 (0.12 to 0.73)) (table 4, ﬁgure 3). None of
the deaths among absent children in the second year
were due to measles infection. A small MV campaign
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was organised on 17 April 1980 for children <6 months
of age in December 1979 and a few of the children
absent in December 1979 may also have received MV in
the April 1980 campaign. When we compared measles-
vaccinated and absent children only between December
1979 and 17 April 1980, the MRR was 0.17 (0.06 to 0.52)
(see online supplementary table 1).
The response to MV is believed to be suboptimal
before maternal antibodies have disappeared completely
after about 12 months of age.6 Hence, it is worth noting
Figure 2 Flow chart of children
taking part in the 1978 and 1979
cohorts.
Table 1 Mortality rates per 100 person-years (deaths/person-years) overall and by sex in Bandim, Guinea-Bissau. Children
aged 0–5 years
Age in months All Females Males
Mortality rate ratio in
females vs males (95% CI)
(A) From 1978 examination, 1 year of follow-up
0–5 14.9 (24/160.5) 14.3 (12/83.9) 15.7 (12/76.7) 0.91 (0.38 to 2.22)
6–11 18.8 (23/122.2) 20.1 (13/64.6) 17.4 (10/57.6) 1.16 (0.47 to 2.95)
12–35 12.5 (57/456.2) 10.7 (25/232.7) 14.3 (32/223.5) 0.75 (0.43 to 1.31)
36–71 2.9 (16/560.3) 2.4 (7/297.1) 3.4 (9/263.2) 0.69 (0.22 to 2.08)
Total* 9.3 (120/1299.2) 8.5 (57/678.3) 10.1 (63/620.9) 0.84 (0.59 to 1.20)
(B) From 1979 examination, 1 year of follow-up
0–5 3.8 (5/131.5) 5.6 (4/71.7) 1.7 (1/59.8) 3.34 (0.33 to 164.3)
6–11 5.8 (8/138.4) 3.4 (2/58.5) 7.5 (6/79.9) 0.46 (0.04 to 2.55)
12–35 4.3 (18/415.4) 4.3 (9/209.2) 4.4 (9/206.2) 0.99 (0.35 to 2.80)
36–71 0.6 (3/489.5) 0.4 (1/254.3) 0.9 (2/235.2) 0.46 (0.01 to 8.88)
Total* 2.8 (34/1174.8) 2.7 (16/593.7) 3.1 (18/581.1) 0.92 (0.46 to 1.82)
*Age-adjusted.
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that the difference between MV vaccinated children
and absent children was marked for children aged
6–11 months at the time of vaccination, the MRR being
0.18 (0.03 to 1.00) (table 4).
Interestingly, the group we assumed to have been
measles vaccinated during the epidemic (‘suspected
MV’) and who were therefore not vaccinated by us had a
mortality rate similar to the rate of the absent children,
the MRR being 1.07 (0.33 to 3.45). We may have misun-
derstood the information about being vaccinated as we
did not explore which vaccine they received during the
epidemic; two children in the ‘suspected MV’ group
died of measles during 1980.2 Alternatively, the MV they
received may have been ineffective because storage con-
ditions were not optimal in the 1970s.
We have previously reported that children who survive
measles infection may have lower mortality than children
who have not had measles infection.7–10 It is therefore
worth noting that the children whose mother declared
in December 1979 that their child had already had
measles infection tended to have lower mortality than
absent children, the MRR being 0.52 (0.13 to 2.10).
Previous studies have suggested that MV has a stronger
beneﬁcial effect for females than for males.11–14 The
present study was too small to address this issue with cer-
tainty (see online supplementary table 2).
DISCUSSION
Main observations
The introduction of MV was linked to a major reduction
in mortality compared with both the mortality rate in
the previous year and the mortality rate of those who
remained measles-unvaccinated. The study also showed
that the beneﬁcial effect of MV was seen for the young-
est children vaccinated at 6–11 months of age.
Strengths and weaknesses
For those who were present and received MV in
December 1979, mortality declined ﬁvefold compared
with the previous year. Bandim experienced a major
measles epidemic causing more than 50% of the deaths
between December 1978 and December 1979,2 so a
large part of this reduction in mortality is explained by
Table 2 Mortality rates per 100 person-years (deaths/person-years) according to presence at 1978 and 1979 examinations
Mortality rate (deaths/person-years)
Age in months Examined Absent
Mortality rate ratio,
examined vs absent (95% CI)
1978 examination
0–5 15.7 (18/114.9) 13.1 (6/45.7) 1.19 (0.45 to 3.67)
6–11 18.2 (18/98.9) 21.5 (5/23.3) 0.85 (0.30 to 2.92)
12–35 13.0 (51/391.8) 9.3 (6/64.4) 1.40 (0.60 to 3.98)
36–71 3.4 (16/472.4) 0 (0/87.9) NA
Total* 9.9 (103/1077.9) 7.2 (17/221.3) 1.35 (0.80 to 2.28)
1979 examination
0–5 4.5 (5/111.1) 0 (0/20.4) NA
6–11 3.4 (4/118.2) 19.8 (4/20.2) 0.17 (0.03 to 0.92)
12–35 3.8 (14/365.6) 8.0 (4/49.8) 0.48 (0.15 to 1.99)
36–71 0.7 (3/427.6) 0 (0/61.9) NA
Total* 2.6 (26/1022.5) 5.2 (8/152.3) 0.49 (0.22 to 1.09)
Children aged 0–5 years.
*Age-adjusted.
NA, not applicable.
Table 3 Mean z-scores for children examined at age 0–4 years in 1978 and in 1979
Weight-for-age z-score
Length/height-for-age
z-score
Weight-for-length/height
z-score*
Age in months 1978 1979 1978 1979 1978 1979
0–5 −0.50 [134] −0.44 [126] −0.61 [134] −0.80 [122] 0.02 [134] 0.37 [121]
6–11 −0.60 [111] −0.71 [134] −0.63 [111] −0.80 [133] −0.28 [111] −0.32 [133]
12–36 −0.85 [436] −1.06 [426] −1.37 [433] −1.49 [425] −0.18 [431] −0.39 [425]
36–60 −0.81 [365] −1.00 [341] −1.41 [363] −1.41 [340] 0.04 [359] −0.25 [339]
All ages −0.76 (1.03) −0.92 (1.03) −1.21 (1.23) −1.29 (1.22) −0.09 (1.03) −0.24 (1.06)
z-score difference† −0.19 (−0.25, −0.14) −0.14 (−0.20, −0.07) −0.16 (−0.23, −0.10)
[ ] is the number of children with a specific z-score in the age group; () is the SD for the z-scores.
*The WHO z-scores are based on measuring length for children under 2 years of age and height for children aged 2 years and older.
†From a random intercept model.
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the absence of measles infection. Still, when we com-
pared measles-vaccinated and measles-unvaccinated chil-
dren in the subsequent year, there was a threefold
difference in mortality. This difference was not
explained by prevention of measles infection as there
were no measles deaths in the absent group during
follow-up.
The children who were not present at the 1979 exam-
ination and therefore did not receive MV could have
been inherently weaker. However, there is little support
for this possibility. In the ﬁrst year, after the 1978 exam-
ination, absent or travelling children did not have
higher mortality than those taking part in the examin-
ation. Furthermore, the children who were absent in
December 1979 had essentially the same mortality rate
as the children who were absent in December 1978
(table 2) and there had not previously been a difference
in nutritional status for the children who were respect-
ively examined or absent at the 1979 examination.
Consistency or contradiction with previous studies
There are only four other studies comparing community
mortality before and after the introduction of MV, three
from Africa and one from India. In all studies, the
reduction in mortality was at least 50%, clearly consistent
with this study from Guinea-Bissau11 12 15 16 and suggest-
ing that MV may prevent more than just measles infec-
tion; it has beneﬁcial non-speciﬁc effects.
There is by now a fairly large number of studies which
have compared mortality of measles-vaccinated and
measles-unvaccinated children either by vaccinating in
some but not in other districts or by comparing vacci-
nated and unvaccinated children within the same
community.6 13
This study suggested a threefold to fourfold lower
mortality among the measles-vaccinated children com-
pared with the measles-unvaccinated children. An effect
of this magnitude in an observational study may appear
‘unbelievable’. Randomised trials were not conducted in
high-mortality countries before the introduction of MV,
so we do not know the ‘true’ effect of MV versus no MV.
However, a few small trials tested the effect of MV versus
no MV in connection with studies of the introduction of
MV before 9 months of age. In a randomised trial in
Sudan, mortality was 91% (29–99%) lower between 5
and 9 months of age for children who received a high-
titre MV compared with control vaccine (meningococcal
vaccine).17 In Guinea-Bissau, children who received MV
at 4.5 months of age in a randomised trial, and had not
received neonatal vitamin A supplementation, had 67%
Table 4 December 1979–1980 mortality rates per 100 person-years (deaths/person-years) according to vaccination status
Mortality rate (deaths/person-years)
Mortality rate ratios
MV vaccinated/absentAge in months
Examined
(MV vaccinated)
Examined
(previous measles)
Examined
(suspected MV) Absent
6–11 3.7 (4/108.8) 0 (0/2.8) 0 (0/6.6) 19.8 (4/20.2) 0.19 (0.03–1.00)
12–35 1.7 (4/238.7) 5.0 (4/80.7) 13.0 (6/46.2) 8.0 (4/49.8) 0.21 (0.04–1.12)
36–71 1.4 (3/208.3) 0 (0/137.7) 0 (0/81.7) 0 (0/61.9) NA
Total* 1.8 (11/555.8) 1.9 (4/221.1) 4.9 (6/134.5) 5.1 (8/131.8) 0.30 (0.12–0.73)
Children aged 6–71 months (eligible for vaccination).
Children who were examined but reported previous measles infection or measles vaccination did not receive MV. Absent children did not
receive MV.
*Age-adjusted.
MV, measles vaccine.
Figure 3 Kaplan-Meier
estimates for children measles
vaccinated or not vaccinated
(absent) at the 1979 examination.
Children with previous measles
infection or suspected measles
vaccination have not been
presented.
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(14–87%) lower mortality than controls randomised to
no vaccine at 4.5 months of age.17 Several natural experi-
ment studies have also suggested very strong effects of
MV on mortality.6
The WHO’s Strategic Advisory Group of Experts
(SAGE) on immunisation recently reviewed the poten-
tial non-speciﬁc effects of BCG, DTP and MV.13 The
review found that BCG and MV almost halved mortality
and this effect was unlikely to be fully explained by pre-
vention of tuberculosis or measles. SAGE concluded that
further studies on the non-speciﬁc effects of vaccines are
warranted.18
The current policy for MV is based on the assump-
tion that it would be better to vaccinate with MV after
12 months of age when maternal antibodies have disap-
peared and the children get a higher antibody
response to MV.19 The only reason that MV is used at
9 months of age in low income countries is that if it
was given at 12 months, too many children would catch
measles before vaccination. Thus, the WHO recom-
mends increasing the age of measles vaccination once
measles infection is under control.20 However, it should
be noted that all existing observations, including this
study, contradict the current policy; in fact, all current
studies suggest that the overall mortality effect of MV is
better when given early.6 The reason is probably that
the non-speciﬁc effects of MV are stronger when the
vaccine is given early. We have recently reported that
children who were measles vaccinated in the presence
of a maternal antibody had much better survival than
children measles vaccinated in the absence of a mater-
nal antibody.21 This would explain why early vaccin-
ation is better because the earlier the vaccine is given,
the more children will still have some maternal
antibody.
Interpretation and implications
The idea that vaccines may have non-speciﬁc effects has
been controversial and very few immunologists have
examined potential mechanisms. However, the evidence
is beginning to emerge. It has been shown that BCG
induces epigenetic changes which reprogramme the
innate immune system to stronger proinﬂammatory
responses. Vaccines may also induce heterologous effects
due to cross-reacting T-cell epitopes.22–24 MV may have
such non-speciﬁc effects on the innate and adaptive
immune system. We recently showed that MV versus no
MV was associated with higher plasma MCP-1 levels. The
effect was signiﬁcant in its own right among females.
Furthermore, MV had signiﬁcantly positive effects on
plasma interleukin (IL)-1Ra and IL-8 levels in females,
but not in males.25
It has recently been suggested by a major paper in
Science that the beneﬁcial non-speciﬁc effects of MV are
due to MV preventing the profound measles-induced
immune amnesia, which is supposed to lead to excess
mortality from other causes than measles infection.26
However, the problem with that hypothesis is that all
available studies7–10—including the present one—
suggest lower mortality rather than excess mortality
among those who survive the acute phase of measles
infection.
All vaccination policies regarding age of vaccination
and number of doses are based entirely on assessment
of the speciﬁc effects of the vaccine. The non-speciﬁc
effects are probably more important than the speciﬁc
effects for overall child survival and should be taken into
consideration when vaccination policies are formulated.
Based on current evidence6 and supported by this study,
the recommendation to increase the age of MV to
12 months should be removed. It should also be consid-
ered changing policy from the current one-dose of MV
to a two-dose schedule with the ﬁrst dose being given
earlier.17 However, the major future problem is what to
do when measles infection has been eliminated or even
eradicated. As long as we do not have a full understand-
ing of the immunological mechanisms inducing beneﬁ-
cial non-speciﬁc effects and have not found alternative
ways of inducing these effects, it would be unwise to
remove the campaigns with MV27 28 and reduce the
number of routine MV. MV has been the strongest pro-
moter of better child health and it might cost dearly if
we stopped or reduced the number of MVs.29
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